Phase I trial of ICRF-159 in combination with 1.3 bis-(2-chloroethyl)-1-nitrosourea (MeCCNU).
Both ICRF-159 and methyl-CCNU are agents with antitumor activity against gastrointestinal carcinoma; hence the exploration of this combination for possible synergism. Results of the study involving 19 patients show that bone marrow toxicity is the limiting factor for this combination of drugs. Moreover, a dose of 130 mg/mg of MeCCNU with 800 mg/m2/day of ICRF is well tolerated.
D001853:Bone Marrow / Q000187:drug effects; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D010879:Piperazines / Q000008:administration & dosage*; D011929:Razoxane / Q000008:administration & dosage* / Q000633:toxicity; D012673:Semustine / Q000008:administration & dosage / Q000633:toxicity
D010879:Piperazines; D012673:Semustine; D011929:Razoxane